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ABSTRACT
Despite a complex cascade of cellular events to reconstruct the damaged extra-
cellular matrix, ligament healing results in a mechanically inferior scarred liga-
ment. During normal healing, granulation tissue expands into any residual
normal ligamentous tissue (creeping substitution), resulting in a larger region of
healing, greater mechanical compromise and an inefficient repair process. To
control creeping substitution and possibly enhance the repair process, the anti-
inflammatory cytokine, interleukin-4 (IL-4), was administered to rats before and
after rupture of their medial collateral ligaments. In vitro experiments showed a
time-dependent effect on fibroblast proliferation after IL-4 treatment. In vivo
treatments with IL-4 (100 ng/mL IV) for 5 days resulted in decreased wound size
and type III collagen and increased type I procollagen, indicating a more regen-
erative early healing in response to the IL-4 treatment. However, continued treat-
ment of IL-4 to day 11 antagonized this early benefit and slowed healing.
Together, these results suggest that IL-4 not only influences the macrophages
and T lymphocytes but also stimulates fibroblasts associated with the prolifera-
tive phase of healing in a dose-, cell-, and time-dependent manner. Although
treatment significantly influenced healing in the first week after injury, IL-4 alone
was unable to maintain this early regenerative response.
Ligament healing involves a complex cascade of events to
reconstruct the damaged tissue, encompassing inflamma-
tion, proliferation, and remodeling processes. Early
wound healing is normally characterized by an up-regula-
tion of neutrophils, macrophages, and T lymphocytes in-
filtrating the injury and a concomitant synthesis and
degradation of the extracellular matrix (ECM). As
mediated by the immune cells, fibroblasts arrive in the
wound-healing region via chemokine signaling, where they
synthesize ECM constituents including type I and type III
collagens. Simultaneously, macrophage-produced MMPs
breakdown collagen, degrading the ECM as part of the re-
modeling process.1,2 This coordinated ECM scar-forming
response during remodeling lasts months or even years and
the injured ligament never fully recovers its original func-
tional properties.3,4 Numerous reports have examined the
influence of biological components on ligament healing,
including matrix metalloproteinases,5,6 cytokines and
growth factors,7–10 stem cells,5,11 and platelet-rich plas-
ma.12,13 To date, no treatment resulted in the complete re-
covery of the injured ligament. Previous research from our
lab characterized the expansion of granulation tissue as
‘‘creeping substitution’’ of the residual ECM.14 Following
ligament injury, granulation tissue forms beyond the orig-
inal injury creeping into the surrounding tissue. The ex-
pansion of granulation tissue to replace residual ECM
results in further ligament degeneration and an inefficient
healing response. A desired healing scenario after injury
would have minimal scar tissue, organized collagen fibers,
restored concentrations of type I collagen, and limited
creeping substitution. Such scenario would reduce type III
collagen, and regenerate the ligament with nearly normal
composition and mechanical properties.
ANOVA Analysis of variance
Daily Day 11 Daily IL-4 injections day 11
dHR Distal healing region
DMEM Dulbecco’s modified Eagle’s medium
ECM Extracellular matrix
EL Epiligament
FBS Fetal bovine serum
FMT Femur–MCL–tibia
H&E Hematoxylin and eosin
HD Day 5 High-dose IL-4 day 5
HR Healing region
IHC Immunohistochemistry
IL-4 Interleukin-4
LD Day 5 Low-dose IL-4 day 5
MCL Medial collateral ligament
MMP Matrix metalloproteinase
MTS [3-(4,5-Dimethylthizaol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt]
N Newtons
OCT Optimal cutting temperature
PBS Phosphate-buffered saline
pHR Proximal healing region
Prox Proximal
A localized increase inM1macrophages that function in
tissue debridement, phagocytosis, and MMP synthesis,
parallels the onset of creeping substitution and therefore
may be a key mediator of the expanding granulation tis-
sue. In contrast, the M2 macrophages promote regenera-
tion by up-regulating antiinflammatory cytokines. A
paucity of M2 macrophages infiltrates the healing liga-
ment. The dominance of M1 over M2 cells may further
exacerbate scar formation.
Interleukin-4 (IL-4) is a pleiotropic cytokine involved in
cell growth, immune system regulation, antiinflammation,
differentiation of T lymphocytes to Th2 lymphocytes, and
promotion of macrophages to the M2 phenotype. Al-
though normally found at low levels in uninjured tissue,
IL-4 increases significantly 1 day after injury and peaks at
4 days before decreasing to normal levels by 21 days.15
This up-regulation of macrophage-produced IL-4 results
in exaggerated collagen and ECM production by fibro-
blasts.16,17 In mouse dermal wounds, daily IL-4 treatments
accelerated the formation of granulation tissue and wound
closure.15 In contrast, healing was delayed in wounds
treated with IL-4-antisense oligonucleotides, although
topical IL-4 administration overrode the delay.15 These
reported effects led to the present study, which was de-
signed to investigate the potential of IL-4 to improve lig-
ament healing. We hypothesized that IL-4 treatment
accelerates healing to control inflammation and reduce
scar formation. Our results indicate that IL-4 treatment to
the injured ligament reduces wound size, decreases type III
collagen, and increases type I procollagen. However,
supplementation of IL-4 alone was unable to maintain
these effects beyond 5 days or increase healing strength of
the ligament.
MATERIALS ANDMETHODS
Cell culture
Fibroblasts from injured and uninjured ligaments were
obtained from MCLs at day 5 postinjury and from intact
rat ligaments as controls. Ligaments were collected from
rats that underwent bilateral surgical ruptures of their
MCLs described below. Five days postinjury, ligaments
were dissected and minced in Hanks’ balanced saline solu-
tion using sterile techniques. Intact MCLs were similarly
collected and processed. Ligament tissue was digested
overnight in filtered 0.5% type IV collagenase (Worthing-
ton, Lakewood, NJ) centrifuged, resuspended in Dulbec-
co’s modified Eagle’s medium (DMEM) containing 10%
fetal bovine serum (FBS), expanded in 75mm2 treated
polystyrene flasks (Corning, Corning, NY) and grown to
confluence. After reaching confluence, cells were trypsini-
zed, counted, and plated at 3103 cells/well in DMEM
containing 2% FBS in tissue-culture-treated Falcon 12-
well polystyrene plates (Becton Dickinson, Franklin
Lakes, NJ). After 24 hours, fibroblasts obtained from the
healing or intact MCLs were separately treated with re-
combinant rat IL-4 (Sigma-Aldrich, St. Louis, MO) at 0,
0.01, 1, or 100 ng/mL containing DMEM and 2% FBS.
Untreated cells (0 ng/mL IL-4) were exposed to medium
containing 2% FBS. Treatments were changed every 24
hours. At 24, 48, and 72 hours posttreatment, cell prolif-
eration was determined using MTS assay (Cell Titer 96
Aqueous One Solution Cell Proliferation Assay, Promega,
Madison, WI).
Animals
This study was approved by the University of Wisconsin
Institutional Animal Use and Care Committee. Thirty-
four skeletally mature male Wistar rats (275–299 g) were
used as an in vivo animal model for ligament healing. All
rats were purchased with fitted external jugular catheters
to enable IV treatment administration. Animals were di-
vided into four experimental groups based on time of col-
lection and dose of IL-4. In experiment 1, animals were
divided into groups of three and subjected to lower doses
of 1 ng/mL of IL-4 (low-dose [LD] Day 5) or phosphate-
buffered saline (PBS) IV until collection at day 5. For
experiment 2, animals were treated with either high doses
of 100 ng/mL IL-4 (high-dose [HD] Day 5) or PBS IV until
collection at day 5 (n53/treatment). Experiment 3 used the
same treatments as experiment 2 but then survived the rats
until day 11 before collection providing a treated (HDDay
11) and control (PBS) group of animals (n58/treatment).
During all experiments, IL-4 or PBS was administered
2 days before surgery (d2), the day of surgery (d0), and
daily thereafter until 4 days postinjury. Finally, experiment
4 animals were treated with IV injections of 100 ng/mL
IL-4 (Daily Day 11) or PBS until the time of sacrifice at
day 11 (n53/treatment). In experiment 4 animals were sub-
jected to IL-4 or PBS injections at d2 and d0 and daily
until 10 days postinjury. Ligaments from three animals per
treatment in all four of the above experiments were col-
lected and used for immunohistochemistry (IHC) and his-
tology. Another five animals/group were included in
experiment 3 for mechanical testing. Mechanical testing
was not performed on day 5 tissue, because the ligament is
too compromised for meaningful mechanical data.
Surgical procedure
Two days before surgery, animals were administered IL-4
or PBS via IV injections into their previously implanted
jugular catheters. Rats were anesthetized (day 0) via
isofluorane. Surgical group rats were then subjected to
bilateral transactions of their MCLs using sterile tech-
niques. MCLs were transected, rather than torn, to create
a uniform defect for healing. A small, 1 cm skin incision
was made over the medial aspect at both the left and right
stifles. The subcutaneous tissue was dissected to expose
the sartorius muscle and underlying MCL. The axial
mid-point of the MCL (determined using a scaled scalpel
handle) was completely transected and the muscular, subcu-
taneous, and subdermal tissue layers were each closed with
4-0 dexon suture. All animals were allowed unrestricted cage
movement immediately after surgery. At 5 and 11 days post-
injury, animals were sacrificed and the MCLs collected.
MCLs were used for IHC or mechanical testing.
Tissue harvest
At the time of sacrifice, the MCLs used for IHC were care-
fully dissected, measured, weighed, and immediately placed
in OCT for flash freezing. Longitudinal cryosections were
then cut at a 5mm thickness, mounted on Superfrost plus
microscope slides, and maintained at70 1C. Animals used
for mechanical testing were sacrificed and stored in toto
at 70 1C until animals were defrosted, MCLs femurs and
tibia were dissected, and MCLs were tested.
Histology
Ligament cryosections were H&E stained to observe gen-
eral morphology of the healing ligaments. After staining,
images were captured and the granulation tissue regions
were measured using Image J.
IHC
Immunostaining was performed on frozen sections using
mouse monoclonal or rabbit polyclonal antibodies. Cryo-
sections were fixed for 10 minutes with acetone, exposed for
5 minutes to 3% hydrogen peroxide to eliminate endo-
genous peroxidase activity, blocked for 30 minutes
with Background Buster (Innovex Biosciences, Richmond,
CA) and incubated with rabbit or mouse primary antibody.
Sections were then incubated with biotin, and streptavidin
conjugated to horseradish peroxidase using the Stat Q stain-
ing kit (Innovex Biosciences). The bound antibody complex
was then visualized using diaminobenzidine. Stained sec-
tions were dehydrated, cleared, cover-slipped, and viewed
using light microscopy. Negative controls omitting the pri-
mary antibody were included with each experiment. Positive
controls of gut or spleen were also included.
Mouse monoclonal antibodies to cell surface markers,
CD68, CD163, and CD3, were used to identify the
classically activated macrophages (M2), alternatively acti-
vated macrophages (M1), and T-lymphocytes, respectively
(all from Abcam-Serotec, Raleigh, NC, at a dilution of
1:100). To identify collagen production, type I procollagen
(straight; SP1.D8; Developmental Hybridoma, Iowa City,
IA) and type III collagen (1 : 8,000, Sigma-Aldrich) mouse
antibodies were used. Endothelial cells were identified us-
ing the polyclonal rabbit antibody thrombomodulin
(1 : 2,500; American Diagnostica, Stamford, CT) and my-
ofibroblasts were identified using a-smooth muscle actin
(straight; Abcam-Serotec).
Quantification
After IHC staining, micrographs were collected using a
camera-assisted microscope (Nikon Eclipse microscope,
model E6000, Nikon Instruments, Inc, Mellville, NY, with
an Olympus camera, model DP79, Olympus Imaging
America, Inc, Center Valley, PA). Six blocked random pic-
tures were obtained from each stained cryosection. Images
were captured at the healing region (HR), the edges of the
healing regions, including the distal healing region (dHR)
and proximal healing region (pHR), the distal (distal) and
proximal (prox) ends of the MCL, and the epiligament
(EL) (Figure 1). Two to three sections were counted per
animal. Granulation tissue measurements, endothelial
cells, myofibroblasts, type I procollagen, and type III col-
lagen were then quantified with Image J (National Insti-
tutes of Health). Images captured for T lymphocytes, and
M1 and M2 macrophages were quantified manually.
Mechanical testing
The mechanical behavior of the MCLs was tested to de-
termine the influence of macrophage inhibition on the
functional integrity of the healing tissue. Pull-to-failure
testing was performed as previously described by Proven-
zano et al.18–20 EachMCL was removed with both femoral
and tibial insertion sites intact. The surrounding tissue was
carefully excised to avoid damaging the insertion sites.
During preparation, the Femur–MCL–tibia (FMT)
complex was kept hydrated using PBS. The width and
thickness of the ligament were measured optically and the
cross-sectional area for the ligament was estimated assum-
ing an elliptical cross section. The FMT complex was
mounted in a custom testing bath and mechanical testing
machine. Optical markers were applied to the ligament on
the insertion sites and the tests were recorded. A preload of
0.1N was applied to the ligament and the MCL was pre-
conditioned (cyclically loaded to approximately 1% strain
for 10 cycles). Dimensional measurements for the ligament
were recorded at the preload. The ligament was then
pulled to failure at a rate of 10% strain per second.
Failure force, failure stress, and stiffness parameters
were all measured to determine ligament functional behav-
ior after treatment. Failure force was recorded as the high-
est load before failure of the ligament and failure stress
was calculated by dividing the failure force by the initial
cross-sectional area measurements. Failure strain was cal-
culated by dividing the change in ligament length during
testing by the initial length of the ligament. Ligament stiff-
ness was defined as the slope of the linear region of the
stress–strain curve. In the linear region, this number is
nearly constant and thus can be calculated by identifying
the linear region and average slope.
Statistical analysis
For cell culture data, a three-way analysis of variance
(ANOVA) analysis was implemented to determine the
Figure 1. Representative cross section of an H&E-stained
healing MCL, indicating the approximate locations subsequent
images were captured for later cell enumeration. Two to three
sections from each animal were examined accordingly. HR,
healing region; pHR, proximal healing region; dHR, distal heal-
ing region; prox, proximal; EL, epiligament; H&E, hematoxylin
and eosin. Original magnification 40.
significance of all main effects and interaction effects (up
to three-factor interaction). Specifically, the main effect
testing included cell effect (‘‘intact’’ vs. ‘‘day 5’’), time
effect (‘‘24 hours,’’ ‘‘48 hours,’’ and ‘‘72 hours’’), and dose
effect (‘‘dose 0,’’ ‘‘dose 0.01,’’ ‘‘dose 1,’’ and ‘‘dose 100’’).
The interactions, celltime, celldose, timedose interac-
tion, and celltimedose were also tested. The three-way
ANOVA analysis of celltimedose interactions was in-
significant. Therefore, a two-way ANOVAmodel in which
all main effects and three two-factor interactions, i.e. (cell,
time), (cell, dose), and (time, dose), was used. A pair-wise
contrast F-test was used for testing the pair-wise differ-
ences between groups.
Ligament regions (Figure 1) were separately analyzed
and pooled into various subgroups (with italicized names
below) to determine any spatial cellular or ECM factor
differences. For IHC analysis, two to three MCL sections
per rat were used (3 rats/treatment). Six blocked random
regions per section were then counted. The total accounts
for the average cell numbers throughout the entire liga-
ment. TheMCL includes the average means of all the sub-
groups excluding the EL. The granulation tissue contains
the HR, pHR, and dHR regions (Figure 1). The ends in-
clude the proximal and distal ligament ends excluding the
granulation tissue and epiligament. Finally, the EL only
considers the EL measurements. All IHC assays were an-
alyzed using one-way ANOVA to observe for treatment
differences (IL-4 and PBS) within the specific subgroups.
Specifically, an F-test was used for testing the overall
difference among treatments. A pair-wise contrast F-test
was used for testing the pair-wise differences between
groups. Mechanical testing data were analyzed via t-tests
(5 rats/treatment). p < 0.05 was used as the criterion for
statistical significance of all experiments. All analyses were
conducted using the statistical software package R-2.9.1.21
RESULTS
Cell proliferation
To determine the in vitro dose effects of IL-4 on fibroblasts
obtained from healing and injured ligaments, IL-4 was
tested on cultured cells. Twenty-four hours posttreatment,
fibroblast proliferation from both the injured and the
intact ligament significantly increased at all concentrations
tested (0.01, 1, and 100 ng/mL IL-4; Figure 2). At 48
hours, IL-4 did not significantly influence fibroblast
proliferation from the intact ligament cells. In contrast,
all tested concentrations of IL-4 inhibited proliferation in
injured ligament fibroblasts. No effects were observed at
72 hours, regardless of cell type (data not shown).
LD (1ng/mL) IL-4 results
In vivo administration of 1 ng/mL IL-4 (experiment 1; n53
rats/treatment) resulted in no significant differences in
granulation tissue area, M2 macrophages, T lymphocytes,
procollagen, type III collagen, or endothelial cells between
the PBS controls. Only theM1macrophages within the EL
were significantly different after IL-4 treatment. Based on
these LD results, a higher dose of IL-4 (100 ng/mL) was
tested in vivo for experiments 2–4.
Morphological measurements/granulation tissue size
To determine the in vivo influence of IL-4 on ligament
healing, area of granulation tissue was measured. Size of
granulation tissue was normalized to the total ligament
area. High doses of IL-4 significantly decreased granula-
tion tissue size (p50.049) at day 5 (Figures 3 and 6A and
B). No other significant effects were observed.
Macrophages and T lymphocytes
Because the probable targets of IL-4-mediated immune
suppression are the T lymphocytes and macrophages,
these cell types were evaluated after IL-4 treatment
(Figure 4). The number of M1 macrophages was reduced
within the EL (p50.001) after LD IL-4 treatment
(103.1 9.5 cells/mm2 PBS vs. 47.1 8.3 cells/mm2 IL-4)
(data not shown). Administering a higher dose of IL-4
tended to decrease the MCL M1 macrophages at day 5
(p50.078), but no other experimental groups or time
points were significantly altered (Figure 4A). On day 5,
the number of M2 cells was not significantly altered after
IL-4 treatment, but daily doses of IL-4 decreased
Figure 2. Dose response of IL-4 on fibroblast proliferation from
cells obtained from uninjured (A) or day 5 postinjured ligaments
(B). Cells were collected at 24, 48, and 72 (not shown) hours
posttreatment and quantified. Error bars represent SEM.
(p50.004) the number of M2 cells within the granulation
tissue at day 11 (Figure 4B). A paucity of T lymphocytes
was identified in the ligament regardless of treatment (Fig-
ure 4C). IL-4 did not significantly influence T-lymphocytes
numbers at day 5 (p > 0.05). However, T-lymphocytes
numbers were diminished in the granulation tissue of the
day 11 ligament from experiment 3 (Figure 4C; p50.03).
Type I and III pro/collagen
To determine whether IL-4 influences the primary colla-
gens involved in ligament healing, collagen type I and III
were analyzed. Type I procollagen increased significantly
(p50.03) in the day 5 ligament after treatment of HD IL-4
(Figures 5A and 6). Concomitantly, type III collagen
MCL levels decreased (p50.003) in response to IL-4 treat-
ment (Figures 5B and 6). This modification of the normal
healing process was transient, however. After cessation of
IL-4 treatment, no other treatment effects were observed
with type I or III collagen on day 11. Continuation of IL-4
treatment resulted in detrimental effects on collagen pro-
duction. Daily doses decreased procollagen type I
(p50.057) while maintaining type III collagen (p50.15),
which is abundant in scar formation. These results agree
with the in vitro data indicating time-dependent effects of
IL-4 on fibroblast proliferation.
Endothelial cells
Studies in other tissues report an inhibitory influence of
IL-4 on angiogenesis.22,23 Therefore, we investigated
endothelial cell localization using IHC. In the day 5
specimens, a HD of IL-4 increased the average number of
endothelial cells within the EL (p50.01; data not shown).
No other day 5 effects were observed. In contrast, IL-4
significantly reduced the number of MCL endothelial cells
in both day 11 groups (HD day 11: p50.03; Daily Day 11:
p50.01) when compared with PBS controls (Figure 7A).
Myofibroblasts
Myofibroblasts are differentiated fibroblasts known to aid in
wound contraction. The LD IL-4 treatment group exhibited
no discernable effects, hence this group was omitted from
further testing. No significant difference (p > 0.05) in
Figure 4. Graph of the M1macrophages (A), M2macrophages
(B), and T lymphocytes (C), at 5 and 11 days postinjury after
PBS or IL-4 treatment (n53 rats/treatment; 21 total rats). On
day 5, high doses of IL-4 (HD Day 5) tended to reduce the MCL
M1 macrophages (p50.078) (A). No differences within the
MCL were observed at any other points. The day 11 healing
region M2 macrophages were significantly reduced after con-
tinuous treatment of IL-4 (Daily Day 11) (B). High doses of IL-4
(HD Day 5) reduced the number of healing region T lympho-
cytes at day 11. #A trend (p < 0.1 between PBS and IL-4 at day
5). nSignificance (p < 0.05) between PBS and IL-4 at day 11 (C).
Values are expressed as mean cell numbersSEM. IL, inter-
leukin; SEM, standard error of mean; MCL, medial collateral lig-
ament; PBS, phosphate-buffered saline; HD, high dose.
Figure 3. Graph of granulation tissue size after IL-4 treatment
(n53 rats/treatment; 21 total rats). High doses of IL-4 significantly
reduced the normalized healing region at day 5 (p < 0.05). No
other significant treatment effects were observed at day 11 or
with low doses of IL-4. Values are the mean percentage of the
granulation tissue area divided by the total ligament areaSEM.
IL, interleukin; SEM, standard error of mean.
granulation tissue-localized myofibroblasts was found in the
day 5 or day 11 HD group when compared with PBS con-
trols (Figure 7B). However, daily administration of IL-4 de-
creased the number myofibroblasts (p50.03).
Spatial localization of IHC factors
To target any cellular or ECM spatial differences after IL-
4 treatment, the total ligament, MCL body, granulation
tissue region, extraneous granulation tissue region, and
the EL were individually analyzed. Treatment primarily
affected IHC factors within the granulation tissue, includ-
ing the T lymphocytes, type I procollagen, endothelial
cells, M2 macrophages, and myofibroblasts. IL-4 was less
influential within the EL and uninjured ligament regions,
affecting only endothelial cells andM1 cells within the EL,
and type I procollagen and type III collagen within the un-
injured regions.
Mechanical testing
To determine if IL-4 treatment affected ligament function,
the day 11 samples (HD day 11) (Figure 8) were mechan-
ically tested. Ligament failure force, failure stress, and
stiffness were measured. No significance difference was
found between IL-4-treated specimens and the PBS con-
trol for any parameter tested (p > 0.05). These results
therefore suggest that IL-4 treatment did not reduce the
mechanical properties of the healing ligament or inhibit
functional recovery.
DISCUSSION
We hypothesized that IL-4 treatment would accelerate
healing by controlling inflammation and reducing scar for-
mation. Results indicate beneficial, albeit transient effects
of IL-4 on ligament healing. The in vitro study reveals a
time-dependent effect of IL-4 on fibroblasts obtained from
normal and injured tissue. It also shows different behav-
iors in fibroblasts from normal and injured tissues. In vivo
administration of IL-4 stimulates early biological healing
in a dose-dependent manner without degrading mechani-
cal recovery compared with normal healing. Finally, con-
tinued IL-4 treatment negates the early benefits in the
observed healing response.
IL-4 is known to control the inflammatory response by
modulating the inflammatory M1/Th1 cells toward a M2/
Th2 pathway, respectively. In the current study at day 5,
high doses of IL-4 accelerated in vivo ligament repair by
reducing wound size, stimulating type I procollagen, and
inhibiting type III collagen. High doses of IL-4 also tended
to reduce M1 macrophages and increase T lymphocytes
without affecting the number of myofibroblasts or endo-
thelial cells. However, the in vivo and in vitro results con-
sistently showed a time-limited response to IL-4. After 24
hours, IL-4 stimulated the in vitro proliferation of fibro-
blasts from tissue obtained from injured and uninjured tis-
sue. In contrast, fibroblasts collected from the injured
ligament were inhibited by IL-4 after 48 hours, and cells
from the uninjured ligament were not. Similarly, in vivo
IL-4 administration up to 4 days beyond injury showed
early regenerative effects (observed at day 5), but these
effects were lost by day 11.
In an attempt to sustain the regenerative effects of IL-4,
an experiment was performed in which IL-4 was adminis-
tered daily until the time of collection at day 11 with the
expectation that sustained IL-4 treatment would maintain
the regenerative response. Studies administering IL-4 to
chronic inflammatory models support this hypothesis. For
example, Horsfall et al.24 administered daily IL-4 treat-
ments to a collagen-induced arthritis (CIA) model. CIA
results in a chronic macrophage response, coinciding with
enhanced tissue damage. Daily IL-4 treatments suppressed
CIA for 28 days. Once IL-4 treatments were halted, arthri-
tis resumed, inflammation elevated, and treated joints were
comparable with the controls.4 These results suggest that
Figure 5. Graph of type I procollagen (A) and type III collagen
(B) after PBS and IL-4 treatment (n53 rats/treatment; 21 total
rats). High doses of IL-4 (HD Day 5) significantly increased
type I procollagen (A) and decreased type III collagen (B) at day
5 within the MCL. However, daily doses of IL-4 (Daily Day 11)
reduced type I collagen (p50.057) (A). No other effects were
observed with type III collage at day 11 (B). nSignificant differ-
ence (p < 0.05) between PBS and IL-4 at day 5 (A and B) or day
11 (A). #A trend (p < 0.1 between PBS and IL-4 at day 11 (Daily
Day 11). Values are expressed as mean positive staining
SEM. IL, interleukin; SEM, standard error of mean; MCL, me-
dial collateral ligament; PBS, phosphate-buffered saline; HD,
high dose.
IL-4 acts on the persistently produced macrophages that
are common to chronic inflammatory conditions.25
Discontinuing IL-4 treatments no longer provided the nec-
essary signals to control the immune cell response, thus
enabling chronic inflammation to resume.25 Our results
indicate that continuous IL-4 administration beyond in-
flammation did not maintain the regenerative response
and in fact inhibited healing and cell proliferation as con-
firmed by the in vivo experiment 4 and the in vitro 48-hour
experiments, respectively. These results suggest that IL-4
accelerates healing during the inflammatory phase, but is
unable to sustain the repair response beyond the inflam-
matory phase of healing at the concentrations of IL-4
tested in this study.
IL-4 is known to influence macrophages and T lympho-
cytes during inflammation but our in vitro and in vivo
Figure 6. Representative micrograph
of H&E (A and B), Type I procollagen
(C–F) and Type III collagen (G and H)
after PBS (left column) or IL-4 (right
side) treatment. Size of the day 5
granulation tissue after PBS (A) or
IL-4 (B) treatment. Black circles are
the same size to compare the granu-
lation size differences between the
two groups (A and B). Type I procolla-
gen IHC of the day 5 ligament after
treatment with PBS (C) or high doses
of IL-4 (D). Type I procollagen IHC of
the day 11 ligament after PBS treat-
ment (E) or daily high doses of IL-4 (F).
Type III collagen IHC of the day 5 lig-
ament after PBS (G) or high doses
of IL-4 (H) treatment. IL, interleukin;
PBS, phosphate-buffered saline; IHC,
immunohistochemistry.
results indicate that IL-4 also influences MCL fibroblasts.
Fibroblasts contain high-affinity IL-4 receptors and ex-
press collagen after IL-4 stimulation.26–28 Huaux et al.29
reported a dual role for IL-4, suggesting that IL-4 acts on
the immune cells during early inflammation and on fibro-
blasts during fibrosis. Although our study only found a
tendency for IL-4 to reduce macrophage numbers, treat-
ment may have altered the macrophage-induced cytokine
release. Numerous studies confirm the ability of IL-4 to
block mononuclear phagocytic cell production of proin-
flammatory cytokines.30–32 In this capacity, IL-4 may play
a beneficial role by limiting early inflammatory signals, but
may also play a detrimental role by promoting scarring
after macrophages subside. Additionally, IL-4 may also
influence the T lymphocytes in our wound-healing model.
At day 11, daily doses of IL-4 significantly reduced the
number of T lymphocytes, possibly signifying a regenera-
tive role for the few T lymphocytes found in the ligament.
The signals that govern regeneration vs. scar during early
and late healing are not fully understood but are believed
to be a coordinated response between macrophages,
T lymphocytes, and fibroblasts.
The discrepancy in the IL-4-induced proliferative re-
sponse between fibroblasts obtained from injured ligament
and fibroblasts obtained from uninjured ligament is a new
finding. During the first 24 hours posttreatment, fibro-
blasts from intact and injured ligaments responded to all
doses of IL-4 tested. By 48 hours posttreatment, IL-4
treatment inhibited fibroblast proliferation from injured
tissue but was not effective on fibroblasts from uninjured
tissue. The difference in cell response to IL-4 may be
Figure 7. Response of endothelial cells (A) and myofibroblasts
(B) to PBS or IL-4 (n53 rats/treatment; 21 total rats). No treat-
ment effects were observed at day 5 (A and B). In contrast, IL-4
significantly reduced the number of MCL endothelial cells at
day 11 (A). Healing region myofibroblasts were also reduced
with daily doses of IL-4 at day 11, whereas injections up to day
4 were not effective (B). nSignificant difference (p < 0.05) be-
tween PBS and IL-4 at day 11 (A and B). Values are expressed
as mean positive stainingSEM. IL, interleukin; SEM, stan-
dard error of mean; MCL,medial collateral ligament; PBS, phos-
phate-buffered saline.
Figure 8. Failure force (A), failure stress (B), and stiffness (C) in
response to PBS or IL-4 treatment 11 days postinjury (n55 rats/
treatment; 10 total rats). No significance in failure force (A) fail-
ure stress (B) or stiffness (C) was observed. p > 0.05. Results
are expressed as meanSEM. IL, interleukin; SEM, standard
error of mean; PBS, phosphate-buffered saline.
attributed to a change in IL-4 receptor number, a change in
affinity of IL-4 to its receptor, the change in cytokine envi-
ronment induced by the wound-healing response, or the
difference in receptor internalization or processing mecha-
nisms to induce proliferation. Further studies are required
to test these concepts.
A desired healing scenario after injury would regenerate
the ligament with nearly normal composition, microstruc-
ture, and mechanical properties. Although IL-4 promoted
early ligament healing, treatment with this factor failed to
improve mechanical or functional properties. The current
results suggest that treatment of multiple IL-4 bolus injec-
tions to the injured ligament is insufficient to suppress scar
tissue formation and improve mechanical properties dur-
ing healing. A number of investigators reported enhanced
biological responses after exogenous growth factor/cyto-
kine treatment but only a few showed increased healing
strength.7–10,33 Continual release of a cytokine treatment
rather than a bolus injection with a limited half-life may
increase efficacy and improve the healing outcome.
Thomopoulos et al.34 demonstrated enhanced biological
tendon healing after bFGF treatment, but no improve-
ment in healing strength. In contrast, gene transfer of
bFGF, resulting in controlled delivery, improved tendon
healing strength.33 In our lab, Provenzano et al.35 showed
increases in healing tissue strength with insulin-like growth
factor-1 and growth hormone. These results suggest that
not only the type and concentration of the cytokine/
growth factor delivered but also the time, duration, and
method of delivery influence healing outcome and me-
chanical behavior.
The current study also compared the spatial differences
of the tested factors between the MCL, EL, healing re-
gions, and uninjured regions after IL-4 treatment. The
effects of IL-4 were primarily observed within the granu-
lation tissue of the healing ligament, whereas few cellular
changes occurred within the EL or the uninjured regions.
Ligament vascularity, cellular differentiation, phagocyto-
sis, and collagen synthesis are primarily localized to the
EL, during normal healing.36–39 However, the current re-
sults imply that IL-4 influences the fibroblasts and/or im-
mune cells within the ligament body, suggesting a direct
influence of IL-4 on the MCL.
Numerous reports have shown macrophage-induced
cytokine modulation, but this study did not. The current
study was not focused on which cells IL-4 influenced, but
rather if IL-4 affected ligament healing via structural and
compositional criteria. Furthermore, fibroblasts were only
studied for the dose-dependent effects of IL-4. Certainly,
the influence of macrophages, T lymphocytes and the co-
culture of these cells with fibroblasts would provide addi-
tional information about the specific cellular dose–
response of IL-4.
In summary, IL-4 enhances ligament regeneration dur-
ing the early phase of MCL healing. With administration
of IL-4, the normally high production of type III collagen
in the healing tissue was reduced while type I procollagen
was stimulated. The response appears more regenerative
of native tissue. However, IL-4 was insufficient to main-
tain these regenerative effects throughout the remodeling
phase of tissue healing, suggesting that other downstream
factors must be considered and modulated in order to
achieve regenerative healing.
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